Angitia Biopharmaceuticals raised $130M Series D venture round, led by Frazier Life Sciences.
This funding round does not have an about section yet.
| Investor | Firm Type | Partner |
|---|
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Private | — | |
| Private Equity | — | |
| Private Equity | — | |
| Hedge Fund | — | |
| Hedge Fund | — | |
| Venture Capital | — | |
| Private | — | |
| Venture Capital | — | |
| Private | — | |
| Venture Capital | — | |
| Private | — | |
| Venture Capital | — |
This company has completed 1 funding round. Current round is highlighted.
Total Raised
$130M
Top Valuation
-
Angitia Biopharmaceuticals raised $130M in a Series D round.
The round was announced on 02/05/26.
The round was led by Frazier Life Sciences, Venrock Healthcare Capital Partners.